» Articles » PMID: 34337075

A Hypoxia Gene-Based Signature to Predict the Survival and Affect the Tumor Immune Microenvironment of Osteosarcoma in Children

Overview
Journal J Immunol Res
Publisher Wiley
Date 2021 Aug 2
PMID 34337075
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Osteosarcoma is a quickly developing, malignant cancer of the bone, which is associated with a bad prognosis. In osteosarcoma, hypoxia promotes the malignant phenotype, which results in a cascade of immunosuppressive processes, poor prognosis, and a high risk of metastasis. Nonetheless, additional methodologies for the study of hyperoxia in the tumor microenvironment also need more analysis. We obtained 88 children patients with osteosarcoma from the Therapeutically Applicable Research to Generate Effective Treatment (TARGET) database and 53 children patients with RNA sequence and clinicopathological data from the Gene Expression Omnibus (GEO). We developed a four-gene signature related to hypoxia to reflect the immune microenvironment in osteosarcoma that predicts survival. A high-risk score indicated a poor prognosis and immunosuppressive microenvironment. The presence of the four-gene signature related to hypoxia was correlated with clinical and molecular features and was an important prognostic predictor for pediatric osteosarcoma patients. In summary, we established and validated a four-gene signature related to hypoxia to forecast recovery and presented an independent prognostic predictor representing overall immune response strength within the osteosarcoma microenvironment.

Citing Articles

Progress in immune microenvironment, immunotherapy and prognostic biomarkers in pediatric osteosarcoma.

Zhang L, Jiang H, Ma H Front Immunol. 2025; 16:1548527.

PMID: 39911380 PMC: 11794274. DOI: 10.3389/fimmu.2025.1548527.


Exploration of metastasis-related signatures in osteosarcoma based on tumor microenvironment by integrated bioinformatic analysis.

Liao S, Gao X, Zhou K, Kang Y, Ji L, Zhong X Heliyon. 2025; 11(1):e41358.

PMID: 39844989 PMC: 11750479. DOI: 10.1016/j.heliyon.2024.e41358.


Prioritizing Context-Dependent Cancer Gene Signatures in Networks.

Capobianco E, Lisse T, Rieger S Cancers (Basel). 2025; 17(1.

PMID: 39796763 PMC: 11720092. DOI: 10.3390/cancers17010136.


Develop a Novel Signature to Predict the Survival and Affect the Immune Microenvironment of Osteosarcoma Patients: Anoikis-Related Genes.

Yang M, Su Y, Xu K, Zheng H, Cai Y, Wen P J Immunol Res. 2024; 2024:6595252.

PMID: 39431237 PMC: 11491172. DOI: 10.1155/2024/6595252.


Large-Scale Comparative Analysis of Canine and Human Osteosarcomas Uncovers Conserved Clinically Relevant Tumor Microenvironment Subtypes.

Patkar S, Mannheimer J, Harmon S, Ramirez C, Mazcko C, Choyke P Clin Cancer Res. 2024; 30(24):5630-5642.

PMID: 39412757 PMC: 11647208. DOI: 10.1158/1078-0432.CCR-24-1854.


References
1.
Qadeer Z, Valle-Garcia D, Hasson D, Sun Z, Cook A, Nguyen C . ATRX In-Frame Fusion Neuroblastoma Is Sensitive to EZH2 Inhibition via Modulation of Neuronal Gene Signatures. Cancer Cell. 2019; 36(5):512-527.e9. PMC: 6851493. DOI: 10.1016/j.ccell.2019.09.002. View

2.
Zhu X, Liu S, Yang X, Wang W, Shao W, Ji T . P4HA1 as an unfavorable prognostic marker promotes cell migration and invasion of glioblastoma via inducing EMT process under hypoxia microenvironment. Am J Cancer Res. 2021; 11(2):590-617. PMC: 7868758. View

3.
Xu L, Deng C, Pang B, Zhang X, Liu W, Liao G . TIP: A Web Server for Resolving Tumor Immunophenotype Profiling. Cancer Res. 2018; 78(23):6575-6580. DOI: 10.1158/0008-5472.CAN-18-0689. View

4.
Ohta A . Oxygen-dependent regulation of immune checkpoint mechanisms. Int Immunol. 2018; 30(8):335-343. DOI: 10.1093/intimm/dxy038. View

5.
Kodama M, Oshikawa K, Shimizu H, Yoshioka S, Takahashi M, Izumi Y . A shift in glutamine nitrogen metabolism contributes to the malignant progression of cancer. Nat Commun. 2020; 11(1):1320. PMC: 7078194. DOI: 10.1038/s41467-020-15136-9. View